FC
PHAS

FORA Capital’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

FORA Capital’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-12,556
Closed -$58K – 1084
2020
Q2 		$58K Buy
+12,556
New +$55.6K 0.02% 611

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

FORA Capital's PHAS Position: Q3 2020 in Review

FORA Capital sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q3 2020, closing a stake of 12,556 shares — an estimated $58K sold.

FORA Capital first reported a position in PHAS in Q2 2020 and held it in 1 quarter. The position peaked at $58K in Q2 2020. 50 funds tracked by Wall St. Rank hold PHAS as of Q3 2020.

  • FORA Capital reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • FORA Capital sold 12,556 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q3 2020, an estimated $58K.
  • FORA Capital first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • FORA Capital's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $58K in Q2 2020.
  • 50 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q3 2020.

Based on FORA Capital's 13F filing for Q3 2020, filed 13 Nov 2020.